Neurophyxia's main objective is to develop 2-iminobiotin (or 2-IB) as a novel injectable pharmaceutical product to reduce the deleterious effects of oxygen shortage in the brain occurring in two life-threatening conditions:

  1. Cardiac arrest in adult patients, which includes the areas of Out of Hospital Cardiac Arrest (OHCA) and In Hospital Cardiac Arrest (IHCA)
  2. Birth asphyxia, also called perinatal asphyxia, in newborn children

Read More »